Anti-ADAM-23 Rabbit Polyclonal Antibody
- Host
- Rabbit, Polyclonal
- Reactivity
- Validated- Human Potential-Mouse, Pan, Monkey, Dog
- UniProt
- O75077
- Size
- 100ug
- Cat. #
- RP1ADAM23
In stock
- SKU
- RP-ADAM23
Target Overview
ADAM-23 (disintegrin and metalloproteinase domain-containing protein 23, UniProt O75077) is a 832-residue cell membrane protein belonging to the ADAM family of zinc-dependent metalloproteases. Unlike most ADAMs, ADAM-23 is catalytically inactive due to structural changes in its metalloprotease domain and is classified as a non-catalytic metalloprotease-like protein. It retains disintegrin, cysteine-rich, and transmembrane domains that mediate cell-cell and cell-matrix interactions. ADAM-23 is predominantly expressed in the central nervous system, where it functions as a receptor component for LGI1 (leucine-rich glioma-inactivated 1). The LGI1-ADAM23 complex regulates synaptic transmission and neuronal excitability, particularly at excitatory synapses. Loss-of-function variants in ADAM23 are associated with epilepsy susceptibility, and the protein has been implicated in autoimmune encephalitis when targeted by anti-LGI1 antibodies. ADAM-23 is also expressed in several cancer types, where it has been studied as a potential tumor suppressor or resistance marker.
Background
ADAM-23 belongs to the ADAM (a disintegrin and metalloproteinase) family but lacks proteolytic activity due to substitutions in critical catalytic residues within its metalloprotease domain. Instead, it functions primarily through protein-protein interactions mediated by its extracellular disintegrin and cysteine-rich domains. The best-characterized interaction partner is LGI1, a secreted protein that bridges ADAM-23 on the presynaptic membrane with ADAM22 postsynaptically. This trans-synaptic complex is essential for normal glutamatergic transmission, and disruption of the LGI1-ADAM23 axis contributes to seizure phenotypes. A recent meta-analysis of nearly 750,000 individuals confirmed rare variant burden in genes encoding the LGI1-ADAM23 protein complex as a significant genetic risk factor for epilepsy, underscoring the clinical relevance of this pathway (Lal et al, 2026, Epilepsia).
ADAM-23 expression is tightly regulated during brain development and exhibits species-specific parent-of-origin expression patterns in certain brain regions, suggesting a role in genomic imprinting and neurodevelopmental programs. In disease contexts beyond epilepsy, ADAM-23 has been detected in autoimmune encephalitis immunoprecipitates alongside LGI1, ADAM22, and DLG4, reflecting its position within a broader synaptic protein network targeted by autoantibodies. Spatiotemporal expression profiling in the mouse dentate gyrus following entorhinal denervation identified ADAM23 among genes dynamically regulated during synaptic reorganization and plasticity.
In oncology, ADAM-23 has emerged as a context-dependent regulator. Recent work in ovarian cancer demonstrated that ADAM-23 expression is modulated by the m6A methyltransferase METTL3 and contributes to platinum resistance, suggesting epitranscriptomic control of ADAM-23 as a therapeutic vulnerability. Two rabbit polyclonal antibodies targeting the cytoplasmic domain of ADAM-23 are available from Triple Point Biologics, validated for Western blot with predicted cross-reactivity in mouse, primate, and dog.
References
- Lal JC et al (2026) Gene burden meta-analysis of 748,879 individuals identifies LGI1-ADAM23 protein complex association with epilepsy. Epilepsia. PubMed · 10.1002/epi.70299
- Kim U et al (2026) Epitranscriptomic Regulation of Platinum Resistance via the METTL3-ADAM23 Axis in Ovarian Cancer. Cells. PubMed · 10.3390/cells15030294
- Meguro-Horike M et al (2026) Species-Specific Parent-Of-Origin Expression of Adam23 in the Mammalian Brain. Genes Cells. PubMed · 10.1111/gtc.70086
- Schlaudraff J et al (2026) Spatiotemporal patterns of gene expression changes in the mouse dentate gyrus following entorhinal denervation. Front Mol Neurosci. PubMed · 10.3389/fnmol.2026.1758390
- Kudo A et al (2026) Association between the peptide spectrum match values of LGI1, ADAM22, ADAM23 and DLG4 in the immunoprecipitation products of five autoimmune encephalitis cases with LGI1 antibody: A case series. Intern Med. PubMed · 10.2169/internalmedicine.6503-25
Additional Specifications
| Size | 100 µg |
|---|---|
| Gene Symbol | ADAM23 |
| UniProt ID | O75077 |
| Host Species | Rabbit |
| Species Reactivity | Validated- Human Potential-Mouse, Pan, Monkey, Dog |
| Pack Size | 100ug |
| Immunogen (Cytoplasmic domain) | Immunogen is proprietary and confidential. Immunogen generated in amino acid region 814-832. |
| Immunogen (Propeptide domain) | Immunogen is proprietary and confidential. Immunogen generated in amino acid region 60-286. |
| Alternate Names | ADAM23, ADAM-23, Disintegrin and metalloproteinase domain-containing protein 23, Metalloproteinase-like, disintegrin-like, and cysteine-rich protein 3, MDC-3, MDC3 |
Frequently Asked Questions
What molecular weight should I expect for ADAM-23 on a Western blot?
ADAM-23 migrates at approximately 95-100 kDa on reducing SDS-PAGE, slightly higher than its calculated mass of 91 kDa due to post-translational glycosylation. The full-length protein comprises 832 residues and contains multiple N-glycosylation sites in its extracellular domain. If you observe a lower band around 70-80 kDa, this may represent a proteolytically processed form or an alternatively spliced isoform, though the dominant species in most neural tissue lysates is the full-length membrane-bound form. Always include a positive control lysate from brain tissue to confirm the expected migration pattern.
What dilution should I start with for Western blot with this ADAM-23 antibody?
Begin at 1:1000 dilution in blocking buffer for Western blot, which is the validated starting point for this rabbit polyclonal. Because ADAM-23 expression is relatively low outside the central nervous system, you may need to optimize between 1:500 and 1:2000 depending on sample type and protein load. Brain lysates typically yield strong signal at 1:1000, while peripheral tissues or cultured neurons may require the higher antibody concentration. Incubate overnight at 4°C for best results. Titrate against your specific lysate rather than assuming the validated dilution is universally optimal.
Does this antibody cross-react with other ADAM family members?
This antibody was raised against a region of human ADAM-23 and has been validated for specificity to ADAM-23 in human samples. While the ADAM family shares structural homology, particularly in metalloprotease and disintegrin domains, cross-reactivity with other ADAM proteins has not been systematically tested. If you are working with samples that co-express ADAM22 or other close relatives, consider running a parallel blot with knockout or knockdown lysates to confirm specificity. The catalytically inactive signature of ADAM-23 distinguishes it functionally, but immunologically, empirical validation in your system is prudent.
Which species can I use this ADAM-23 antibody with?
This antibody is validated for human ADAM-23 and shows predicted cross-reactivity with mouse, non-human primate, and dog based on sequence homology in the epitope region. If working with mouse or rat brain lysates, expect signal but verify with appropriate positive and negative controls, as we have not formally validated these species. Primate samples are highly likely to work given the high conservation of ADAM-23 across primates. For other species, BLAST the immunogen sequence against your target organism before committing to experiments. Homology above 85 percent in the epitope region generally predicts useful reactivity.
What positive control tissue should I use for ADAM-23 Western blots?
Use whole brain lysate or hippocampal tissue from human, mouse, or rat as your positive control, as ADAM-23 is predominantly expressed in the central nervous system. Cortex and hippocampus show particularly high expression. Cerebellar lysate also works well. Avoid using HEK293 or HeLa lysates as negative controls without verifying endogenous expression levels first; many transformed cell lines show aberrant ADAM-23 expression. If working with primary neurons, differentiated cultures at DIV7 or later typically express detectable ADAM-23. Commercial brain lysates are available and provide consistent lot-to-lot performance for method development.
Can I use this antibody for immunofluorescence or immunohistochemistry on brain sections?
Yes, Triple Point Biologics antibodies are validated for Western blot; immunofluorescence and IHC application data is in progress. For IHC on paraffin-embedded brain sections, antigen retrieval is typically required; citrate buffer pH 6.0 with heat-mediated retrieval works well for most membrane proteins. Start with a 1:100 to 1:200 dilution and optimize from there. For immunofluorescence on fixed cultured neurons, try 1:200 after permeabilization with 0.1-0.3 percent Triton X-100. Because ADAM-23 is a membrane protein, expect punctate staining at synapses and along dendrites in neurons co-labeled with synaptic markers.
How should I store this antibody and what is the expected shelf life?
Store the antibody at -20°C in small aliquots to avoid repeated freeze-thaw cycles, which can reduce titer and increase aggregation. The 100 µg pack size is suitable for dividing into 10-20 µL aliquots depending on your experimental throughput. Once thawed, an aliquot can be kept at 4°C for up to one month if sodium azide is present as preservative. Do not store diluted antibody in working solutions for more than one week. Under proper storage at -20°C, rabbit polyclonal antibodies typically retain activity for three to five years, though we recommend using within two years of receipt for optimal performance.
Why does ADAM-23 lack catalytic activity if it is a metalloprotease?
ADAM-23 contains a structurally degenerate metalloprotease domain that lacks the catalytic residues required for proteolytic activity, specifically mutations in the zinc-binding consensus sequence. It functions instead as a scaffolding and adhesion molecule, particularly as a receptor for LGI1 in synaptic signaling. This has practical implications for your experiments: ADAM-23 will not cleave substrates in biochemical assays, and its function is mediated through protein-protein interactions via its disintegrin and cysteine-rich domains. When interpreting results, consider ADAM-23 as a regulatory receptor rather than an enzyme, distinguishing it from catalytically active family members like ADAM10 or ADAM17.
Validation imagery coming soon
Western blot validation figures for RP-ADAM23 will be published here as they are produced in-house.
If you would like to see existing validation data for this antibody before publication, request a sample copy.
Also known as:
- ADAM23
- ADAM-23
- Disintegrin and metalloproteinase domain-containing protein 23
- Metalloproteinase-like
- disintegrin-like
- and cysteine-rich protein 3
- MDC-3
- MDC3